Effect of particle size on solubility, dissolution rate, and oral bioavailability: Evaluation using coenzyme Q10 as naked nanocrystals

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5733-5744

  Sun, Jiao ^a   Wang, Fan ^a,b   Sui, Yue ^a   She, Zhennan ^a   Zhai, Wenjun ^a   Wang, Chunling ^a   Deng, Yihui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Beijing Zhijianjinrui Applied Pharmaceutical Science Inc   (China)

Author keywords

Bioavailability; Coenzyme Q10; Dissolution; Nanocrystal; Particle size; Solubility

Indexed keywords

NANOCRYSTAL; UBIDECARENONE;

AREA UNDER THE CURVE; ARTICLE; BULK DENSITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; EQUILIBRIUM CONSTANT; EXPERIMENTAL DOG; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; MATERIALS TESTING; MOUTH; NANOPARTICLES; PARTICLE SIZE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; UBIQUINONE;

CANIS FAMILIARIS;

EID: 84870342804     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34365     Document Type: Article

References (32)

1. Gassmann P, List M, Schweitzer A, Sucker H. Hydrosols-alternatives for the parenteral application of poorly water soluble drugs. Eur J Pharm Biopharm. 1994;40(2):64-72.
2. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19.
3. Dolenc A, Kristl J, Baumgartner S, Planinsek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376(122):204-212.
4. Jinno J, Kamada N, Miyake M, etal. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111(1/2):56-64.
5. Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm. 1998;160(2):229-237.
6. Dong Y, Ng WK, Shen S, Kim S, Tan RBH. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm. 2009;375(1/2):84-88.
7. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631-644.
8. Mauludin R, Müller RH, Keck CM. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm Sci. 2009;36(4/5): 502-510.
9. Mosharraf M, Nyström C. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm. 1995;122(1/2):35-47.
10. Wu W, Nancollas GH. A new understanding of the relationship between solubility and particle size. J Solution Chem. 1998;27(6):521-531.
11. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284(1/2): 109-122.
12. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19(12):930-934.
13. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to the Biopharmaceutics Classification System. Int J Pharm. 2006;321(1):1-11.
14. Babu VR, Areefulla S, Mallikarjun V. Solubility and dissolution enhancement: an overview. J Pharm Res. 2010;3(1):141-145.
15. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409(1/2): 260-268.
16. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm. 2006;312(1/2):179-186.
17. Rao GC, Kumar MS, Mathivanan N, Rao ME. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie. 2004;59(1):5-9.
18. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785-796.
19. Matteucci ME, Hotze MA, Johnston KP, Williams RO. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir. 2006;22(21):8951-8959.
20. Zhang JY, Shen ZG, Zhong J, etal. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm. 2006;323(1/2):153-160.
21. Zhang X, Xia Q, Gu N. Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug Dev Ind Pharm. 2006;32(7):857-863.
22. Baba K, Pudavar HE, Roy I, etal. New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug. Mol Pharm. 2007;4(2):289-297.
23. Wang F, Sun J, Deng YH. Relationship between particle size and solubility of coenzyme Q10 nanosuspensions. J Shenyang Pharm Univ. 2010;27(12):933-939.
24. Sun J, Deng YH, Ma YL, Han J. Equilibrium solubility of naked nanocrystals is not related to particle size. J Shenyang Pharm Univ. 2011;28(08):585-593.
25. Ankola D, Viswanad B, Bhardwaj V, Ramarao P, Kumar M. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? EurJ Pharm Biopharm. 2007;67(2):361-369.
26. Sheridan PL, Buckton G, Storey DE. The extent of errors associated with contact angles II. Factors affecting data obtained using a Wilhelmy plate technique for powders. Int J Pharm. 1994;109(2):155-171.
27. Anderberg EK, Bisrat M, Nyström C. Physicochemical aspects of drug release. VII. The effect of surfactant concentration and drug particle size on solubility and dissolution rate of felodipine, a sparingly soluble drug. Int J Pharm. 1988;47(1/3):67-77.
28. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA. What is a suitable dissolution method for drug nanoparticles? Pharm Res. 2008;25(7): 1696-1701.
29. Van Eerdenbrugh B, Vermant J, Martens JA, etal. Solubility increases associated with crystalline drug nanoparticles: methodologies and significance. Mol Pharm. 2010;16(7):1858-1870.
30. Bergstrom CA, Wassvik CM, Johansson K, Hubatsch I. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem. 2007;50(23):5858-5862.
31. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 2005;299(1/2):167-177.
32. Palamakula A, Soliman M, Khan MM. Regional permeability of coenzyme Q10 in isolated rat gastrointestinal tracts. Pharmazie. 2005;60(3):212-214.